Search research articles
Contact Us
Filters
Showing results (21-30 of 45) with videos related to
Page
of 5
Sort By:
Biochemistry
|
December 19, 2001
Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities
A Litovchick, A Lapidot, M Eisenstein, et al.
Experimental and Molecular Pathology
|
October 1, 1992
Ultrastructural alterations in mouse capillary blood vessels after experimental injection of venom from the snake Bothrops asper (Terciopelo)
L Moreira, J M Gutiérrez, G Borkow, et al.
Biochemistry
|
December 8, 1998
Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase
D Arion, N Kaushik, S McCormick, et al.
Antimicrobial Agents and Chemotherapy
|
January 30, 1999
The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1
G Borkow, D Arion, M A Wainberg, et al.
Toxicon : Official Journal of the International Society on Toxinology
|
January 1, 1995
Isolation and characterization of a metalloproteinase with weak hemorrhagic activity from the venom of the snake Bothrops asper (terciopelo)
J M Gutiérrez, M Romero, C Díaz, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
July 27, 2001
Immune activation correlates better than HIV plasma viral load with CD4 T-cell decline during HIV infection
Q Leng, G Borkow, Z Weisman, et al.
Clinical Immunology (Orlando, Fla.)
|
June 21, 2001
Increased CCR5 and CXCR4 expression in Ethiopians living in Israel: environmental and constitutive factors
A Kalinkovich, G Borkow, Z Weisman, et al.
AIDS (London, England)
|
December 1, 1996
Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase
M A Wainberg, M Hsu, Z Gu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 9, 1999
Infection by different HIV-1 subtypes (B and C) results in a similar immune activation profile despite distinct immune backgrounds
Z Weisman, A Kalinkovich, G Borkow, et al.
The Journal of Biological Chemistry
|
August 16, 1996
The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase
D Arion, G Borkow, Z Gu, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 45) with videos related to
Sort By:
Page
of 5
Biochemistry
|
December 19, 2001
Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities
A Litovchick, A Lapidot, M Eisenstein, et al.
Experimental and Molecular Pathology
|
October 1, 1992
Ultrastructural alterations in mouse capillary blood vessels after experimental injection of venom from the snake Bothrops asper (Terciopelo)
L Moreira, J M Gutiérrez, G Borkow, et al.
Biochemistry
|
December 8, 1998
Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase
D Arion, N Kaushik, S McCormick, et al.
Antimicrobial Agents and Chemotherapy
|
January 30, 1999
The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1
G Borkow, D Arion, M A Wainberg, et al.
Toxicon : Official Journal of the International Society on Toxinology
|
January 1, 1995
Isolation and characterization of a metalloproteinase with weak hemorrhagic activity from the venom of the snake Bothrops asper (terciopelo)
J M Gutiérrez, M Romero, C Díaz, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
July 27, 2001
Immune activation correlates better than HIV plasma viral load with CD4 T-cell decline during HIV infection
Q Leng, G Borkow, Z Weisman, et al.
Clinical Immunology (Orlando, Fla.)
|
June 21, 2001
Increased CCR5 and CXCR4 expression in Ethiopians living in Israel: environmental and constitutive factors
A Kalinkovich, G Borkow, Z Weisman, et al.
AIDS (London, England)
|
December 1, 1996
Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase
M A Wainberg, M Hsu, Z Gu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 9, 1999
Infection by different HIV-1 subtypes (B and C) results in a similar immune activation profile despite distinct immune backgrounds
Z Weisman, A Kalinkovich, G Borkow, et al.
The Journal of Biological Chemistry
|
August 16, 1996
The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase
D Arion, G Borkow, Z Gu, et al.
Page
of 5